# Moffitt Cancer Center
**Type:** Institutions
**Canonical URL:** https://scholariq.org/institutions/moffitt-cancer-center/
## Facts
| Field | Value |
| --- | --- |
| Avg h-index | 65.6 |
| Citations | 4,553,201 |
| City | Tampa |
| Country | US |
| Description | Moffitt Cancer Center is a research organisation in Tampa, US. OpenAlex records 37,929 works and 4,553,201 citations for it. 7,250 researchers list it as their most recent affiliation. |
| Homepage | https://www.moffitt.org |
| OpenAlex ID | https://openalex.org/I3019308854 |
| Region | Florida |
| Researchers | 7,250 |
| ROR ID | https://ror.org/01xf75524 |
| Type | healthcare |
| Works | 37,929 |
## University collaborators
- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)
- [Vanderbilt University Medical Center](https://scholariq.org/institutions/vanderbilt-university-medical-center/)
- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)
- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)
- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)
- [Melanoma Institute Australia](https://scholariq.org/institutions/melanoma-institute-australia/)
- [Bristol-Myers Squibb (United States)](https://scholariq.org/institutions/bristol-myers-squibb-united-states/)
## University papers
Showing 12 of 190.
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer](https://scholariq.org/papers/human-papillomavirus-and-survival-of-patients-with-oropharyngeal-cancer/)
- [Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Final Version of 2009 AJCC Melanoma Staging and Classification](https://scholariq.org/papers/final-version-of-2009-ajcc-melanoma-staging-and-classification/)
- [Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
- [Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [B cells and tertiary lymphoid structures promote immunotherapy response](https://scholariq.org/papers/b-cells-and-tertiary-lymphoid-structures-promote-immunotherapy-response/)
- [A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer](https://scholariq.org/papers/a-randomized-trial-of-bevacizumab-an-anti-vascular-endothelial-growth-factor/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial](https://scholariq.org/papers/oral-poly-adp-ribose-polymerase-inhibitor-olaparib-in-patients-with-brca1-or/)
## University researchers
- [Jhanelle E. Gray](https://scholariq.org/researchers/jhanelle-e-gray/)
- [Eric B. Haura](https://scholariq.org/researchers/eric-b-haura/)
- [Jonathan Strosberg](https://scholariq.org/researchers/jonathan-strosberg/)
- [Larry K. Kvols](https://scholariq.org/researchers/larry-k-kvols/)
- [Alberto Chiappori](https://scholariq.org/researchers/alberto-chiappori/)
- [Jane L. Messina](https://scholariq.org/researchers/jane-l-messina/)
- [Alison Walker](https://scholariq.org/researchers/alison-walker/)
- [Ben Creelan](https://scholariq.org/researchers/ben-creelan/)
- [Kedar Kirtane](https://scholariq.org/researchers/kedar-kirtane/)
- [Timothy Kubal](https://scholariq.org/researchers/timothy-kubal/)
- [Satish Maharaj](https://scholariq.org/researchers/satish-maharaj/)
## University top topics
Showing 8 of 25.
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.